Meet the Startup Building a Firewall for DNA — Before AI Can Weaponize It
Valthos has emerged from stealth with a $30 million seed round and a critical mission: to defend the world against AI-powered bioattacks. Backed by OpenAI’s Startup Fund, Lux Capital, and former Google CEO Eric Schmidt, the company is building a security platform tailored to the unique risks posed by synthetic biology and generative AI. The round also includes backing from SV Angel, Coalition Operators, and top-tier biotech and tech angels, signaling broad conviction in the urgency and potential impact of Valthos' work.
At its core, Valthos is building an "intelligent firewall" for biology — a system that evaluates whether genetic sequences are safe or malicious. As AI models become capable of designing pathogens or optimizing biological functions at unprecedented speed, traditional safeguards like DNA sequence screening are no longer enough. Valthos’ platform aims to assess the intent and capability of code in real-time, functioning like a cybersecurity layer for biological information. That means evaluating whether a snippet of DNA could encode a dangerous toxin, or if a synthetic biology experiment could be misused — before it ever hits a lab.
What sets Valthos apart is its fusion of AI security and biosecurity into a new category of infrastructure. The team includes veterans from Anthropic, Google DeepMind, and OpenAI, alongside bioengineers and national security experts. The company isn’t just building for the academic or scientific community — it’s also targeting synthetic biology platforms, DNA printers, cloud labs, and national agencies that will need robust defenses as biological R&D becomes more distributed and AI-assisted.
With bioengineering entering a generative era, the risk of unintentional — or deliberate — misuse is rising fast. Valthos is positioning itself as the infrastructure layer that ensures innovation doesn’t outpace safety. In a world where one bad actor with a high-powered model could design a pathogen, Valthos is building the gatekeeper. This round is not just a funding milestone; it’s a wake-up call for the ecosystem to invest in biosecurity tech before it’s too late.
Sources: Valthos
Bloomberg
The News
M.A.
